These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 10407502)

  • 1. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS).
    Nishimura S; Sekiguchi M; Kano T; Ishiwata S; Nagasaki F; Nishide T; Okimoto T; Kutsumi Y; Kuwabara Y; Takatsu F; Nishikawa H; Daida H; Yamaguchi H
    Atherosclerosis; 1999 Jun; 144(2):409-17. PubMed ID: 10407502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein-apheresis: 1-year follow-up study. The Osaka LDL-Apheresis Multicenter Trial Group.
    Kitabatake A; Sato H; Hori M; Kamada T; Kubori S; Hoki N; Minamino T; Yamada M; Kato T
    Clin Ther; 1994; 16(3):416-28. PubMed ID: 7923308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis.
    Thompson GR; Maher VM; Matthews S; Kitano Y; Neuwirth C; Shortt MB; Davies G; Rees A; Mir A; Prescott RJ
    Lancet; 1995 Apr; 345(8953):811-6. PubMed ID: 7898227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART).
    Matsuzaki M; Hiramori K; Imaizumi T; Kitabatake A; Hishida H; Nomura M; Fujii T; Sakuma I; Fukami K; Honda T; Ogawa H; Yamagishi M
    J Am Coll Cardiol; 2002 Jul; 40(2):220-7. PubMed ID: 12106923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia.
    Richter WO; Donner MG; Höfling B; Schwandt P
    Metabolism; 1998 Jul; 47(7):863-8. PubMed ID: 9667236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical application and effectiveness of low-density lipoprotein apheresis in the treatment of coronary artery disease.
    Daida H; Yamaguchi H
    Ther Apher; 1997 Aug; 1(3):253-4. PubMed ID: 10225748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.
    Mabuchi H; Koizumi J; Shimizu M; Kajinami K; Miyamoto S; Ueda K; Takegoshi T
    Am J Cardiol; 1998 Dec; 82(12):1489-95. PubMed ID: 9874053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A case of heterozygous familial hypercholesterolemia showing the regression of coronary atherosclerosis by LDL-apheresis].
    Nomura S; Kouzuma R; Komura T; Sadayasu T; Segawa J; Nakashima Y; Kuroiwa A
    Kokyu To Junkan; 1992 Mar; 40(3):299-302. PubMed ID: 1579754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease.
    Kroon AA; van Asten WN; Stalenhoef AF
    Ann Intern Med; 1996 Dec; 125(12):945-54. PubMed ID: 8967704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS).
    Aengevaeren WR; Kroon AA; Stalenhoef AF; Uijen GJ; van der Werf T
    J Am Coll Cardiol; 1996 Dec; 28(7):1696-704. PubMed ID: 8962554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).
    Waldmann E; Vogt A; Crispin A; Altenhofer J; Riks I; Parhofer KG
    Atherosclerosis; 2017 Apr; 259():20-25. PubMed ID: 28279833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marked aortic valve stenosis progression after receiving long-term aggressive cholesterol-lowering therapy using low-density lipoprotein apheresis in a patient with familial hypercholesterolemia.
    Tsuchida M; Kawashiri MA; Tada H; Takata M; Nohara A; Ino H; Inazu A; Kobayashi J; Koizumi J; Mabuchi H; Yamagishi M
    Circ J; 2009 May; 73(5):963-6. PubMed ID: 19088396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. The LARS Investigators.
    Tatami R; Inoue N; Itoh H; Kishino B; Koga N; Nakashima Y; Nishide T; Okamura K; Saito Y; Teramoto T
    Atherosclerosis; 1992 Jul; 95(1):1-13. PubMed ID: 1642687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten-year follow-up of familial hypercholesterolemia patients after intensive cholesterol-lowering therapy.
    Masaki N; Tatami R; Kumamoto T; Izawa A; Shimada Y; Takamatsu T; Katsushika S; Ishise S; Maruyama Y; Yoshimoto N
    Int Heart J; 2005 Sep; 46(5):833-43. PubMed ID: 16272774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
    Kawashiri MA; Nohara A; Higashikata T; Tada H; Nakanishi C; Okada H; Konno T; Sakata K; Hayashi K; Inazu A; Mabuchi H; Yamagishi M
    Atherosclerosis; 2017 Oct; 265():225-230. PubMed ID: 28926730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term effect of LDL apheresis on coronary heart disease.
    Donner MG; Richter WO; Schwandt P
    Eur J Med Res; 1997 Jun; 2(6):270-4. PubMed ID: 9182655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coronary artery bypass grafting in familial hypercholesterolemia.
    Kawasuji M; Sakakibara N; Takemura H; Matsumoto Y; Mabuchi H; Watanabe Y
    J Thorac Cardiovasc Surg; 1995 Feb; 109(2):364-9. PubMed ID: 7853888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The retardation of progression, stabilization, and regression of coronary and carotid atherosclerosis by low-density lipoprotein apheresis in patients with familial hypercholesterolemia.
    Koga N
    Ther Apher; 1997 Aug; 1(3):260-70. PubMed ID: 10225750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis.
    Kroon AA; Aengevaeren WR; van der Werf T; Uijen GJ; Reiber JH; Bruschke AV; Stalenhoef AF
    Circulation; 1996 May; 93(10):1826-35. PubMed ID: 8635262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol.
    Lappegård KT; Enebakk T; Thunhaug H; Hovland A
    Atherosclerosis; 2016 Aug; 251():119-123. PubMed ID: 27318831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.